These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22015772)

  • 41. Advances in the discovery of selective JAK inhibitors.
    Menet CJ; Rompaey LV; Geney R
    Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. JAK2 inhibition for the treatment of hematologic and solid malignancies.
    Harry BL; Eckhardt SG; Jimeno A
    Expert Opin Investig Drugs; 2012 May; 21(5):637-55. PubMed ID: 22493978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition.
    Leroy E; Constantinescu SN
    Leukemia; 2017 May; 31(5):1023-1038. PubMed ID: 28119526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
    Yang EG; Mustafa N; Tan EC; Poulsen A; Ramanujulu PM; Chng WJ; Yen JJ; Dymock BW
    J Med Chem; 2016 Sep; 59(18):8233-62. PubMed ID: 27541357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.
    Zak M; Hurley CA; Ward SI; Bergeron P; Barrett K; Balazs M; Blair WS; Bull R; Chakravarty P; Chang C; Crackett P; Deshmukh G; DeVoss J; Dragovich PS; Eigenbrot C; Ellwood C; Gaines S; Ghilardi N; Gibbons P; Gradl S; Gribling P; Hamman C; Harstad E; Hewitt P; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Labadie S; Lee WP; Liao J; Liimatta M; Mendonca R; Narukulla R; Pulk R; Reeve A; Savage S; Shia S; Steffek M; Ubhayakar S; van Abbema A; Aliagas I; Avitabile-Woo B; Xiao Y; Yang J; Kulagowski JJ
    J Med Chem; 2013 Jun; 56(11):4764-85. PubMed ID: 23659214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ni-Catalyzed C-H Functionalization in the Formation of a Complex Heterocycle: Synthesis of the Potent JAK2 Inhibitor BMS-911543.
    Fitzgerald MA; Soltani O; Wei C; Skliar D; Zheng B; Li J; Albrecht J; Schmidt M; Mahoney M; Fox RJ; Tran K; Zhu K; Eastgate MD
    J Org Chem; 2015 Jun; 80(12):6001-11. PubMed ID: 25848821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening.
    Pölläniemi A; Virtanen A; Silvennoinen O; Haikarainen T
    SLAS Discov; 2023 Jun; 28(4):180-187. PubMed ID: 37149038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thiophene carboxamide inhibitors of JAK2 as potential treatments for myleoproliferative neoplasms.
    Haidle AM; Zabierek AA; Childers KK; Rosenstein C; Mathur A; Altman MD; Chan G; Xu L; Bachman E; Mo JR; Bouthillette M; Rush T; Tempest P; Marshall CG; Young JR
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1968-73. PubMed ID: 24666646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors.
    Baskin R; Majumder A; Sayeski PP
    Curr Med Chem; 2010; 17(36):4551-8. PubMed ID: 21062251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Computer-aided discovery of aminopyridines as novel JAK2 inhibitors.
    Zhao C; Yang SH; Khadka DB; Jin Y; Lee KT; Cho WJ
    Bioorg Med Chem; 2015 Mar; 23(5):985-95. PubMed ID: 25650310
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modification of CellSensor irf1-bla TF-1 and irf1-bla HEL assays for direct comparison of wild-type JAK2 and JAK2 V617F inhibition.
    Mason JL; Holskin BP; Murray KA; Meyer SL; Wells-Knecht KJ; Ator MA; Angeles TS
    Assay Drug Dev Technol; 2011 Jun; 9(3):311-8. PubMed ID: 21133674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation.
    Li JJ; Cheng P; Tu J; Zhai HL; Zhang XY
    Mol Biosyst; 2016 Feb; 12(2):575-87. PubMed ID: 26687880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.
    McDonnell ME; Bian H; Wrobel J; Smith GR; Liang S; Ma H; Reitz AB
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1116-21. PubMed ID: 24461299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia.
    Geissler K; Jäger E; Barna A; Sliwa T; Knöbl P; Schwarzinger I; Gisslinger H; Valent P
    Eur J Haematol; 2016 Dec; 97(6):562-567. PubMed ID: 27157043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.
    Gäbler K; Rolvering C; Kaczor J; Eulenfeld R; Méndez SÁ; Berchem G; Palissot V; Behrmann I; Haan C
    J Cell Mol Med; 2013 Feb; 17(2):265-76. PubMed ID: 23301855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis of Biotinylated 2-methoxystypandrone and Identification of JAK2 and IKK as its Targets.
    Kuang S; Sima Z; Liu J; Li W; Song Q; Zhang Q; Yu Q
    Anticancer Agents Med Chem; 2018; 18(3):422-427. PubMed ID: 29110628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments.
    Majumder A; Kirabo A; Karrupiah K; Tsuda S; Caldwell-Busby J; Cardounel AJ; Keseru GM; Sayeski PP
    Biochemistry; 2011 Sep; 50(36):7774-86. PubMed ID: 21823612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.
    Bar-Natan M; Nelson EA; Walker SR; Kuang Y; Distel RJ; Frank DA
    Leukemia; 2012 Jun; 26(6):1407-10. PubMed ID: 22134716
    [No Abstract]   [Full Text] [Related]  

  • 59. 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.
    Siu M; Pastor R; Liu W; Barrett K; Berry M; Blair WS; Chang C; Chen JZ; Eigenbrot C; Ghilardi N; Gibbons P; He H; Hurley CA; Kenny JR; Cyrus Khojasteh S; Le H; Lee L; Lyssikatos JP; Magnuson S; Pulk R; Tsui V; Ultsch M; Xiao Y; Zhu BY; Sampath D
    Bioorg Med Chem Lett; 2013 Sep; 23(17):5014-21. PubMed ID: 23870430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective JAK inhibitors.
    Dymock BW; Yang EG; Chu-Farseeva Y; Yao L
    Future Med Chem; 2014; 6(12):1439-71. PubMed ID: 25329199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.